| ACADIA PHARMACEUTICALS |
| USA |
| Gesundheit |
| US0042251084 / 603035 |
| DR6 (Frankfurt) / ACAD (NASDAQ) |
| FRA:DR6, ETR:DR6, DR6:GR, NASDAQ:ACAD |
| - |
| https://acadia.com/ |
|
Acadia Pharmaceuticals Inc. is a biopharmaceutical company focused on developing and commercializing medicines for neurological disorders and rare diseases. The company’s primary purpose is to address conditions with significant unmet medical needs..
>Volltext.. |
| 3808.58 Mio. EUR |
| 3116.41 Mio. EUR |
| 962.1 Mio. EUR |
| 81.44 Mio. EUR |
| 329.98 Mio. EUR |
| 1.95 EUR |
| 44.62 Mio. EUR |
| 247.9 Mio. EUR |
| 108.48 Mio. EUR |
| 2.79 |
| 2.94% |
| 53.68% |
| - |
| - |
| - |
| - |
| ACADIA PHARMACEUTICALS, ACADIA PHARMA |
| 29.06.26 |